GlassScriptPhysician profile
Mona R Gupta
NPI 1902923691
$88,223.20
in general payments reported to CMS, 2019-2025
37 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $8,143 · 2021: $22K · 2022: $19K · 2023: $9,471 · 2024: $2,898 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,404 · Food and Beverage: $3,577 · Consulting Fee: $3,000 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,000 · Travel and Lodging: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,404.00 |
| Food and Beverage | $3,577.43 |
| Consulting Fee | $3,000.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,000.00 |
| Travel and Lodging | $811.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22,554.77 | 2019-2025 | Rexulti |
| Allergan, INC. | $16,277.65 | 2019-2021 | |
| Alkermes, INC. | $13,761.87 | 2019-2025 | Aristada, Vivitrol, Lybalvi |
| Abbvie INC. | $9,628.57 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $7,726.55 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $6,503.96 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $4,242.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $2,135.31 | 2019-2025 | Spravato, Invega Sustenna |
| Neuronetics, INC. | $791.52 | 2019-2022 | |
| Lundbeck LLC | $592.87 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $521.38 | 2019-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $490.28 | 2020-2025 | Uzedy, Austedo, Austedo Xr |
| Bausch Health US, LLC | $368.28 | 2019-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $349.96 | 2019-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $235.37 | 2020-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.